Chapter 5: Major Multi-Stakeholder Initiatives — Defining the Future of COVID-19 Observational Research


  1. COVID-19 Map. Johns Hopkins Coronavirus Resource Center. Accessed January 11, 2022.
  2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533-534. doi:10.1016/S1473-3099(20)30120-1
  3. CSSEGISandData. COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.; 2022. Accessed January 11, 2022.…
  4. Home | Margolis Center for Health Policy. Accessed January 11, 2022.
  5. McClellan M, Gottlieb S, Allen J, Borio L, Tenaerts P. Building the Critical Path for COVID-19 Therapeutics. Published online May 20, 2020. Accessed January 18, 2022.…
  6. U.S. Food and Drug Administration. Coronavirus Disease 2019 (COVID-19). Published January 14, 2022. Accessed January 18, 2022.…
  7. OHDSI – Observational Health Data Sciences and Informatics. Accessed January 11, 2022.
  8. Data Standardization – OHDSI. Accessed January 11, 2022.
  9. Software Tools – OHDSI. Accessed January 11, 2022.
  10. Chen R, Ryan P, Natarajan K, et al. Treatment Patterns for Chronic Comorbid Conditions in Patients With Cancer Using a Large-Scale Observational Data Network. JCO Clinical Cancer Informatics. 2020;4. doi:10.1200/CCI.19.00107
  11. European Health Data Evidence Network. Accessed January 11, 2022.
  12. COVID19 Study-a-thon 2020. Accessed January 11, 2022.
  13. OHDSI Studies. GitHub. Accessed January 11, 2022.
  14. COVID-19 Updates Page – OHDSI. Accessed January 11, 2022.
  15. List of OHDSI Working Groups. Observational Health Data Sciences and Informatics. Accessed January 11, 2022.
  16. Burn E, You SC, Sena AG, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020;11(1):5009. doi:10.1038/s41467-020-18849-z
  17. Morales DR, Conover MM, You SC, et al. Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. The Lancet Digital Health. 2021;3(2):e98-e114. doi:10.1016/S2589-7500(20)30289-2
  18. Lane JCE, Weaver J, Kostka K, et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. The Lancet Rheumatology. 2020;2(11):e698-e711. doi:10.1016/S2665-9913(20)30276-9
  19. Duarte-Salles T, Vizcaya D, Pistillo A, et al. Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience. Pediatrics. 2021;148(3):e2020042929. doi:10.1542/peds.2020-042929
  20. Tan EH, Sena AG, Prats-Uribe A, et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology. 2021;60(SI):SI37-SI50. doi:10.1093/rheumatology/keab250
  21. Recalde M, Roel E, Pistillo A, et al. Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. Int J Obes. 2021;45(11):2347-2357. doi:10.1038/s41366-021-00893-4
  22. Roel E, Pistillo A, Recalde M, et al. Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. Cancer Epidemiol Biomarkers Prev. 2021;30(10):1884-1894. doi:10.1158/1055-9965.EPI-21-0266
  23. Prats-Uribe A, Sena AG, Lai LYH, et al. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study. BMJ. Published online May 11, 2021:n1038. doi:10.1136/bmj.n1038
  24. Reps JM, Kim C, Williams RD, et al. Implementation of the COVID-19 Vulnerability Index Across an International Network of Health Care Data Sets: Collaborative External Validation Study. JMIR Med Inform. 2021;9(4):e21547. doi:10.2196/21547
  25. Homepage | Sentinel Initiative. Accessed January 11, 2022.
  26. Center for Drug Evaluation and Research. FDA’s Sentinel Initiative. FDA. Published October 18, 2019. Accessed January 11, 2022.
  27. How Sentinel Gets Its Data | Sentinel Initiative. Accessed January 11, 2022.
  28. U.S. Food and Drug Administration. Office of Counterterrorism and Emerging Threats. Published December 8, 2021. Accessed January 11, 2022.
  29. Methods, Data, & Tools | Sentinel Initiative. Accessed January 11, 2022.
  30. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. Published online September 1, 2020:m3320. doi:10.1136/bmj.m3320
  31. Ellington S, Strid P, Tong VT, et al. Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–June 7, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):769-775. doi:10.15585/mmwr.mm6925a1
  32. Cocoros NM, Fuller CC, Adimadhyam S, et al. A COVID‐19‐ready public health surveillance system: The Food and Drug Administration’s Sentinel System. Pharmacoepidemiol Drug Saf. 2021;30(7):827-837. doi:10.1002/pds.5240
  33. Master Protocol Development: COVID-19 Natural History | Sentinel Initiative. Accessed January 11, 2022.…
  34. Perez-Vilar S, Martinez AI, Shinde M, et al. Outpatient-Identified COVID-19 and Subsequent Hospitalized Thrombotic Events. :4.
  35. Kempner ME, Shinde M, Hartman J, Lyons J, Stojanovic D, Kit B. Natural History of Coagulopathy in Patients with COVID-19 in a Real-World Electronic Health Data Network. :23.
  36. Martinez AI, Perez-Vilar S, Shinde M, et al. Comparing outcomes in trial-eligible vs real-world COVID-19 patients: The case of invasive mechanical ventilation. Pharmacoepidemiology and Drug Safety. Published online 2021:97-97.
  37. Shinde M, Andrade S, Lyons JG, et al. COVID-19 Pregnancy Study Protocol. Published online May 19, 2021. Accessed January 11, 2022.
  38. Near Real-Time Monitoring of Critical Drugs for the Care of Patients with COVID-19 | Sentinel Initiative. Accessed January 11, 2022.…
  39. U.S. Food and Drug Administration. In Brief: FDA Provides Guidance on Master Protocols for Evaluating Prevention, Treatment Options for COVID-19. FDA. Published May 17, 2021. Accessed January 11, 2022.…
  40. OpenSAFELY: Home. Accessed January 11, 2022.
  41. Oxford DataLab | Practical health data analytics. Accessed January 11, 2022.
  42. Electronic Health Records (EHR) Research Group. LSHTM. Accessed January 11, 2022.
  43. Release files from the server - OpenSAFELY documentation. Accessed January 11, 2022.
  44. OpenCodelists. Accessed January 11, 2022.
  45. ICNARC – Intensive Care National Audit & Research Centre. Accessed January 11, 2022.
  46. ISARIC • ISARIC. Accessed January 11, 2022.
  47. SGSS and CHESS data. NHS Digital. Accessed January 11, 2022.…
  48. The OpenSAFELY Collaborative, Curtis HJ, Inglesby P, et al. Trends and Clinical Characteristics of COVID-19 Vaccine Recipients: A Federated Analysis of 57.9 Million Patients’ Primary Care Records in Situ Using OpenSAFELY. Public and Global Health; 2021. doi:10.1101/2021.01.25.21250356
  49. The Health Service (Control of Patient Information) Regulations 2002. Accessed January 11, 2022.
  50. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4
  51. Bhaskaran K, Bacon S, Evans SJ, et al. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. The Lancet Regional Health - Europe. 2021;6:100109. doi:10.1016/j.lanepe.2021.100109
  52. Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8(11):1106-1120. doi:10.1016/S2213-2600(20)30415-X
  53. COVID-19 Rapid Guideline: Severe Asthma. National Institute for Health and Care Excellence (NICE); 2020. Accessed January 11, 2022.
  54. Rentsch CT, DeVito NJ, MacKenna B, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. The Lancet Rheumatology. 2021;3(1):e19-e27. doi:10.1016/S2665-9913(20)30378-7
  55. Wong AY, MacKenna B, Morton CE, et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021;80(7):943-951. doi:10.1136/annrheumdis-2020-219517
  56. Mathur R, Rentsch CT, Morton CE, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. The Lancet. 2021;397(10286):1711-1724. doi:10.1016/S0140-6736(21)00634-6
  57. Williamson EJ, McDonald HI, Bhaskaran K, et al. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. BMJ. Published online July 14, 2021:n1592. doi:10.1136/bmj.n1592
  58. Forbes H, Morton CE, Bacon S, et al. Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England. BMJ. Published online March 18, 2021:n628. doi:10.1136/bmj.n628
  59. Walker AJ, MacKenna B, Inglesby P, et al. Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. Br J Gen Pract. 2021;71(712):e806-e814. doi:10.3399/BJGP.2021.0301
  60. OpenSAFELY: secure access to data to deepen our understanding of COVID-19. NHSX. Accessed January 11, 2022.…
  61. Oxford Population Health. Ben Goldacre - OpenSAFELY.Org.; 2021. Accessed January 11, 2022.
  62. Sturkenboom M, Bahri P, Chiucchiuini A, et al. Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines. Vaccine. 2020;38:B1-B7. doi:10.1016/j.vaccine.2019.07.081
  63. Thurin NH, Pajouheshnia R, Roberto G, et al. From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. Clin Pharma and Therapeutics. 2022;111(1):321-331. doi:10.1002/cpt.2476
  64. Trifirò G, Coloma PM, Rijnbeek PR, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014;275(6):551-561. doi:10.1111/joim.12159
  65. Willame, C, Dodd, C, Gini, R, et al. Background Rates of Adverse Events of Special Interest for Monitoring COVID-19 Vaccines. Zenodo; 2021. doi:10.5281/ZENODO.5255870
  66. A post-authorisation/post-marketing observational study to evaluate the association between exposure to AZD1222 and safety concerns using existing secondary health data sources (COVID-19). ENCEPP. Accessed June 9, 2022.
  67. An Observational Post-Authorization Safety Study to Assess the Safety of Ad26.COV2.S Using European Healthcare Data through VAC4EU (COVID-19). ENCEPP. Accessed June 9, 2022.
  68. Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine. ENCEPP. Accessed June 9, 2022.
  69. Monitoring safety of Spikevax in pregnancy: an observational study using routinely collected health data in five European countries (COVID-19). ENCEPP. Accessed June 9, 2022.
  70. COVID-19 Research Database. COVID-19 Research Database. Accessed January 11, 2022.
  71. Talwai A, Wing V, Itzkovich Y, et al. PIN83 The COVID-19 Research Database: Building One of the Largest PRO Bono Real-World DATA Repositories. Value in Health. 2021;24:S121. doi:10.1016/j.jval.2021.04.1271
  72. Lekoubou A, Pelton M, Ba DM, Ssentongo P. Racial Disparities in Ischemic Stroke Among Patients with COVID-19 in the United States. Journal of Stroke and Cerebrovascular Diseases. 2021;30(8):105877. doi:10.1016/j.jstrokecerebrovasdis.2021.105877
  73. Nguyen TD, Gupta S, Ziedan E, et al. Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic. JAMA Intern Med. 2021;181(4):562. doi:10.1001/jamainternmed.2020.7497
  74. Meiselbach MK, Bai G, Anderson GF. Charges of COVID-19 Diagnostic Testing and Antibody Testing Across Facility Types and States. J GEN INTERN MED. Published online September 15, 2020. doi:10.1007/s11606-020-06198-y
  75. O’Donoghue AL, Biswas N, Dechen T, et al. Trends in Filled Naloxone Prescriptions Before and During the COVID-19 Pandemic in the United States. JAMA Health Forum. 2021;2(5):e210393. doi:10.1001/jamahealthforum.2021.0393
  76. French DD, Chin A, Kathail P. Further Evidence that COVID-19 Disproportionately Impacts African American, Hispanic, and Low-Income Populations. Medium. Published June 16, 2020. Accessed January 11, 2022.…
  77. Galaznik A, Rusli E, Wing V, Jain R, Diamond S, Fajgenbaum D. Assessment of vitamin D deficiency and COVID-19 diagnosis in patients with breast or prostate cancer using electronic medical records. JCO. 2021;39(15_suppl):6589-6589. doi:10.1200/JCO.2021.39.15_suppl.6589
  78. Wing V, Rusli E, Jain R, Galaznik A, Diamond S, Fajgenbaum D. Vitamin D deficiency: Risk of COVID-19 and public health implications. In: APHA; 2021. Accessed January 11, 2022.
  79. Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. JAMA Netw Open. 2020;3(9):e2019722. doi:10.1001/jamanetworkopen.2020.19722
  80. COVIDRIVE – A public-private partnership for the estimation of brand-specific COVID-19 vaccine effectiveness in Europe. Accessed January 11, 2022.
  81. European Medicines Agency. Consideration on core requirements for RMPs of COVID-19 vaccines. Published online June 10, 2021. Accessed January 11, 2022.…
  82. DRIVE - Development of Robust and Innovative Vaccine Effectiveness  Increasing understanding of influenza vaccine effectiveness in Europe. DRIVE. Accessed January 11, 2022.
  83. Study Contributors – COVIDRIVE. Accessed January 11, 2022.
  84. Bollaerts K, Biccler J, Stuurman A, Aponte Z, Hartig-Merkel W, Rebry G. Master Protocol: Brand-specific COVID-19 vaccine effectiveness against severe COVID-19 disease in Europe. :100.
  85. View Study. Accessed January 11, 2022.
  86. New Public-private Partnership COVIDRIVE To Assess brand-specific COVID-19 Vaccine Effectiveness In Europe. Published online July 19, 2021. Accessed January 11, 2022.…